179 related articles for article (PubMed ID: 21187922)
1. Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.
Yu KD; Huang AJ; Shao ZM
PLoS One; 2010 Dec; 5(12):e15649. PubMed ID: 21187922
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
[TBL] [Abstract][Full Text] [Related]
5. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
6. A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.
Park GC; Jung JA; Bae KS; Lim HS
J Clin Pharmacol; 2017 Sep; 57(9):1088-1096. PubMed ID: 28369967
[TBL] [Abstract][Full Text] [Related]
7. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.
Sukasem C; Sirachainan E; Chamnanphon M; Pechatanan K; Sirisinha T; Ativitavas T; Panvichian R; Ratanatharathorn V; Trachu N; Chantratita W
Asian Pac J Cancer Prev; 2012; 13(9):4549-53. PubMed ID: 23167378
[TBL] [Abstract][Full Text] [Related]
9. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Gurwitz D; Newman W
J Natl Cancer Inst; 2008 Sep; 100(18):1331; author reply 1332-4. PubMed ID: 18780871
[No Abstract] [Full Text] [Related]
10. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
Seruga B; Amir E
Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.
Zeng Z; Liu Y; Liu Z; You J; Chen Z; Wang J; Peng Q; Xie L; Li R; Li S; Qin X
Cancer Chemother Pharmacol; 2013 Aug; 72(2):287-303. PubMed ID: 23712329
[TBL] [Abstract][Full Text] [Related]
14. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Woods B; Veenstra D; Hawkins N
Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Goetz MP; Rae JM; Suman VJ; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Flockhart DA; Desta Z; Perez EA; Ingle JN
J Clin Oncol; 2005 Dec; 23(36):9312-8. PubMed ID: 16361630
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Province MA; Goetz MP; Brauch H; Flockhart DA; Hebert JM; Whaley R; Suman VJ; Schroth W; Winter S; Zembutsu H; Mushiroda T; Newman WG; Lee MT; Ambrosone CB; Beckmann MW; Choi JY; Dieudonné AS; Fasching PA; Ferraldeschi R; Gong L; Haschke-Becher E; Howell A; Jordan LB; Hamann U; Kiyotani K; Krippl P; Lambrechts D; Latif A; Langsenlehner U; Lorizio W; Neven P; Nguyen AT; Park BW; Purdie CA; Quinlan P; Renner W; Schmidt M; Schwab M; Shin JG; Stingl JC; Wegman P; Wingren S; Wu AH; Ziv E; Zirpoli G; Thompson AM; Jordan VC; Nakamura Y; Altman RB; Ames MM; Weinshilboum RM; Eichelbaum M; Ingle JN; Klein TE;
Clin Pharmacol Ther; 2014 Feb; 95(2):216-27. PubMed ID: 24060820
[TBL] [Abstract][Full Text] [Related]
17. The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR; Helft P
Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
Kiyotani K; Mushiroda T; Sasa M; Bando Y; Sumitomo I; Hosono N; Kubo M; Nakamura Y; Zembutsu H
Cancer Sci; 2008 May; 99(5):995-9. PubMed ID: 18294285
[TBL] [Abstract][Full Text] [Related]
19. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
20. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
Lan B; Ma F; Zhai X; Li Q; Chen S; Wang J; Fan Y; Luo Y; Cai R; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Jul; 143(1):184-189. PubMed ID: 29396856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
